Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.52 |
| ▸ | LSS | P48449 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL10520510 | 0.92 | DRD2 (0.50) | QDPRDRD2DRD4DRD3GRM2 | |
| SCHEMBL13416045 | 0.90 | DRD2 (0.51) | DRD2DRD4DRD3GRM2SLC6A2 | |
| SCHEMBL10265025 | 0.84 | DRD2 (0.47) | DRD2DRD4DRD3GRM2SLC6A2 | |
| SCHEMBL1067433 | 0.82 | SLC6A3 (0.53) | DRD2DRD4DRD3GRM2SLC6A2 | |
| SCHEMBL29940424 | 0.82 | SLC6A3 (0.53) | DRD2DRD4DRD3GRM2SLC6A2 | |
| SCHEMBL23585205 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MDM2 | |
| SCHEMBL10057673 | 0.81 | MCOLN2 (0.55) | DRD2DRD4DRD3GRM2SLC6A2 | |
| SCHEMBL10078309 | 0.81 | QDPR (0.50) | QDPRDRD2DRD4GRM2LSS | |
| SCHEMBL11027883 | 0.80 | DRD2 (0.54) | DRD2DRD4DRD3GRM2SLC6A4 | |
| SCHEMBL13416036 | 0.80 | DRD3 (0.63) | DRD2DRD4DRD3LSSSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| EP-3468961-B1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20100144701-A1 | Modulators of CB1 Receptors | 7TM PHARMA A/S (DK) | 2010-06-10 | — | — | US | disclosed |
| US-7320978-B2 | Oxazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-7320978-B2 | Oxazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144701-A1 | Modulators of CB1 Receptors | CNR1, CNR2, GPR6 | QDPR 2143/4885DRD2 415/4885DRD4 726/4885 |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | QDPR 550/4885DRD2 491/4885DRD4 1799/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | QDPR 3183/4885DRD2 3081/4885DRD4 4348/4885 |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | OXA1L, ARG2, CYP3A7 | QDPR 102/4885DRD2 1146/4885DRD4 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.